Monitor for potential downward pressure on sentiment given coordinated C-suite selling, especially if followed by additional divestitures or weak earnings. The modest size limits immediate impact, but the concentration among senior executives is a cautionary signal.
ZLAB drugs
ZLAB drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider transactions at Zai Lab Ltd (ZLAB) over the past week shows one director buying $32.7K in shares while three C-suite executives, including the CFO and Chief Legal Officer, sold a combined $110.5K in stock. The net activity is modest selling, with total open-market dispositions exceeding purchases by over 3-to-1.
Key Financial Metrics
Key Facts
- Director Richard Gaynor purchased 1,731 shares for $32,733 in an open-market transaction.
- CFO Yajing Chen sold 1,703 shares for $31,723, Chief Legal Officer Titus Edmondson sold 1,281 shares for $23,862, and executive Joshua Smiley sold 1,966 shares for $36,623.
- All sales occurred on March 13, 2026, at $18.628 per share, totaling $111,209 in open-market selling by insiders.
- Total net open-market value: $78,476 in sales after purchase, representing 0.0037% of ZLAB's $2.1B market cap.
- Selling was concentrated among senior executives, including two C-suite officers.
Financial Impact
$78.5K net open-market selling by insiders, driven by C-suite executives
Risk Factors
- Perception of insider lack of confidence, particularly with CFO and legal chief selling simultaneously.
- Risk of negative interpretation if no offsetting positive news emerges in near term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (5 trades, 7d window) | cluster-ZLAB-1773950780276 |
Track record
23 reports on ZLAB
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.13% at T+20 after the May 7, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $22.60 to $25.48 Now $23.47 +3.85% ▲ +12.74% +12.43% vs SPY
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $24.03 to $24.34 Now $23.47 −2.33% ▲ +1.29% +0.58% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $25.64 to $26.17 Now $23.47 −8.46% ▲ +2.07% +1.75% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 12, 202613w ago 144 Neutral 2/10 Entry $25.49 to $26.03 Now $23.47 −7.92% ▲ +2.12% +1.42% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $19.12 to $19.08 Now $23.47 +22.75% ▼ −0.21% −1.08% vs SPY
- Jun 29, 202620w ago Insider Cluster Neutral 3/10 Entry $19.00 to $19.15 Now $23.47 +23.53% ▲ +0.79% +0.92% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $17.64 to $17.07 Now $23.47 −33.05% ▲ +3.23% +3.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers